Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Small molecules > afatinib


Tuesday 10 June 2014


Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok) is an angiokinase inhibitor approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim.

It acts as an angiokinase inhibitor.